\babel@toc {english}{}\relax 
\contentsline {part}{I\hspace {1em}Notes}{7}{part.1}%
\contentsline {chapter}{\numberline {1}Introduction}{8}{chapter.1}%
\contentsline {section}{\numberline {1.1}Genetics and genomics}{8}{section.1.1}%
\contentsline {subsection}{\numberline {1.1.1}Genetics}{8}{subsection.1.1.1}%
\contentsline {subsection}{\numberline {1.1.2}Genomics}{8}{subsection.1.1.2}%
\contentsline {subsection}{\numberline {1.1.3}Differences between genetics and genomics}{8}{subsection.1.1.3}%
\contentsline {subsection}{\numberline {1.1.4}The role of computational biology}{9}{subsection.1.1.4}%
\contentsline {section}{\numberline {1.2}Basis of human genomics}{9}{section.1.2}%
\contentsline {subsection}{\numberline {1.2.1}Single nucleotide polymorphisms}{9}{subsection.1.2.1}%
\contentsline {subsection}{\numberline {1.2.2}Copy number variants}{9}{subsection.1.2.2}%
\contentsline {subsection}{\numberline {1.2.3}Inherited variants}{9}{subsection.1.2.3}%
\contentsline {subsubsection}{\numberline {1.2.3.1}Penetrance}{10}{subsubsection.1.2.3.1}%
\contentsline {subsubsection}{\numberline {1.2.3.2}Allele frequency}{10}{subsubsection.1.2.3.2}%
\contentsline {subsubsection}{\numberline {1.2.3.3}Differences in Genetic Make-Up, an example}{10}{subsubsection.1.2.3.3}%
\contentsline {subsection}{\numberline {1.2.4}Somatic Variants}{11}{subsection.1.2.4}%
\contentsline {subsubsection}{\numberline {1.2.4.1}Classification}{11}{subsubsection.1.2.4.1}%
\contentsline {subsubsection}{\numberline {1.2.4.2}Types of acquired DNA aberrations}{11}{subsubsection.1.2.4.2}%
\contentsline {paragraph}{\numberline {1.2.4.2.1}Translocation}{11}{paragraph.1.2.4.2.1}%
\contentsline {paragraph}{\numberline {1.2.4.2.2}Inversion}{11}{paragraph.1.2.4.2.2}%
\contentsline {paragraph}{\numberline {1.2.4.2.3}Copy number changes}{12}{paragraph.1.2.4.2.3}%
\contentsline {paragraph}{\numberline {1.2.4.2.4}Chromoplexy}{12}{paragraph.1.2.4.2.4}%
\contentsline {section}{\numberline {1.3}Experimental techniques to detect variants/aberrations}{12}{section.1.3}%
\contentsline {subsection}{\numberline {1.3.1}Karyotyping}{12}{subsection.1.3.1}%
\contentsline {subsection}{\numberline {1.3.2}Sequence capture for cancer genomics}{12}{subsection.1.3.2}%
\contentsline {subsubsection}{\numberline {1.3.2.1}Reference}{12}{subsubsection.1.3.2.1}%
\contentsline {subsubsection}{\numberline {1.3.2.2}Deepness}{13}{subsubsection.1.3.2.2}%
\contentsline {subsubsection}{\numberline {1.3.2.3}Single End (SE) and Paired End (PE) reads}{13}{subsubsection.1.3.2.3}%
\contentsline {paragraph}{\numberline {1.3.2.3.1}Single end sequencing}{13}{paragraph.1.3.2.3.1}%
\contentsline {paragraph}{\numberline {1.3.2.3.2}Paired end sequencing}{13}{paragraph.1.3.2.3.2}%
\contentsline {paragraph}{\numberline {1.3.2.3.3}Ability of paired end sequencing to detect genomic aberrations}{13}{paragraph.1.3.2.3.3}%
\contentsline {chapter}{\numberline {2}Coverage}{14}{chapter.2}%
\contentsline {section}{\numberline {2.1}Computing coverage}{14}{section.2.1}%
\contentsline {subsection}{\numberline {2.1.1}Local coverage}{14}{subsection.2.1.1}%
\contentsline {subsection}{\numberline {2.1.2}Allelic fraction}{14}{subsection.2.1.2}%
\contentsline {subsection}{\numberline {2.1.3}NGS global coverage}{14}{subsection.2.1.3}%
\contentsline {section}{\numberline {2.2}Mapping in NGS}{14}{section.2.2}%
\contentsline {subsection}{\numberline {2.2.1}Sequence coverage}{15}{subsection.2.2.1}%
\contentsline {subsection}{\numberline {2.2.2}Physical coverage}{15}{subsection.2.2.2}%
\contentsline {section}{\numberline {2.3}Tuning coverage}{15}{section.2.3}%
\contentsline {subsection}{\numberline {2.3.1}SNP detection}{15}{subsection.2.3.1}%
\contentsline {subsection}{\numberline {2.3.2}Subclonal events}{15}{subsection.2.3.2}%
\contentsline {subsection}{\numberline {2.3.3}Amplicon-based approaches}{16}{subsection.2.3.3}%
\contentsline {subsubsection}{\numberline {2.3.3.1}Heterozygous deletion of PTEN}{16}{subsubsection.2.3.3.1}%
\contentsline {subsubsection}{\numberline {2.3.3.2}Homozygous deletion of PTEN}{16}{subsubsection.2.3.3.2}%
\contentsline {subsubsection}{\numberline {2.3.3.3}Amplification of AR}{16}{subsubsection.2.3.3.3}%
\contentsline {subsection}{\numberline {2.3.4}NGS-based approaches}{17}{subsection.2.3.4}%
\contentsline {subsubsection}{\numberline {2.3.4.1}Advantages over amplicon-based approaches}{17}{subsubsection.2.3.4.1}%
\contentsline {subsubsection}{\numberline {2.3.4.2}Problems of NGS-based approaches}{17}{subsubsection.2.3.4.2}%
\contentsline {section}{\numberline {2.4}Databases for NGS analysis}{17}{section.2.4}%
\contentsline {subsection}{\numberline {2.4.1}Genome reference consortium}{17}{subsection.2.4.1}%
\contentsline {subsection}{\numberline {2.4.2}USCS genome browser}{17}{subsection.2.4.2}%
\contentsline {chapter}{\numberline {3}Genetic Fingerprinting}{18}{chapter.3}%
\contentsline {section}{\numberline {3.1}Introduction}{18}{section.3.1}%
\contentsline {subsection}{\numberline {3.1.1}Fields of interest}{18}{subsection.3.1.1}%
\contentsline {subsection}{\numberline {3.1.2}Variants used for genetic testing}{18}{subsection.3.1.2}%
\contentsline {subsubsection}{\numberline {3.1.2.1}CNVs}{18}{subsubsection.3.1.2.1}%
\contentsline {subsubsection}{\numberline {3.1.2.2}SNPs}{19}{subsubsection.3.1.2.2}%
\contentsline {section}{\numberline {3.2}SNPs features}{19}{section.3.2}%
\contentsline {subsection}{\numberline {3.2.1}Hardy-Weinberg equilibrium}{19}{subsection.3.2.1}%
\contentsline {subsection}{\numberline {3.2.2}Minor allele frequency}{19}{subsection.3.2.2}%
\contentsline {subsubsection}{\numberline {3.2.2.1}Optimal MAF values for genetic fingerprinting}{19}{subsubsection.3.2.2.1}%
\contentsline {subsection}{\numberline {3.2.3}Haplotype blocks}{20}{subsection.3.2.3}%
\contentsline {subsubsection}{\numberline {3.2.3.1}Linkage disequilibrium}{20}{subsubsection.3.2.3.1}%
\contentsline {subsubsection}{\numberline {3.2.3.2}Tag SNPs}{20}{subsubsection.3.2.3.2}%
\contentsline {subsection}{\numberline {3.2.4}Other SNP features}{21}{subsection.3.2.4}%
\contentsline {subsection}{\numberline {3.2.5}Number of SNPs to select when performing a genetic test}{21}{subsection.3.2.5}%
\contentsline {subsubsection}{\numberline {3.2.5.1}Experimental mismatches - Genotype call error rate}{21}{subsubsection.3.2.5.1}%
\contentsline {paragraph}{\numberline {3.2.5.1.1}An example on the effect of experimental mismatches}{22}{figure.caption.12}%
\contentsline {subsubsection}{\numberline {3.2.5.2}Biological mismatches}{22}{subsubsection.3.2.5.2}%
\contentsline {paragraph}{\numberline {3.2.5.2.1}Loss of Heterozygosity (LOH)}{22}{paragraph.3.2.5.2.1}%
\contentsline {paragraph}{\numberline {3.2.5.2.2}Gain Of Heterozygosity (GOH)}{22}{paragraph.3.2.5.2.2}%
\contentsline {paragraph}{\numberline {3.2.5.2.3}Double Mutation (DM)}{22}{paragraph.3.2.5.2.3}%
\contentsline {paragraph}{\numberline {3.2.5.2.4}Modelling biological mismatches}{22}{paragraph.3.2.5.2.4}%
\contentsline {subsection}{\numberline {3.2.6}Project regarding SNPs}{23}{subsection.3.2.6}%
\contentsline {subsubsection}{\numberline {3.2.6.1}dbSNPs}{23}{subsubsection.3.2.6.1}%
\contentsline {subsubsection}{\numberline {3.2.6.2}HapMap3}{23}{subsubsection.3.2.6.2}%
\contentsline {section}{\numberline {3.3}Genetic distance}{23}{section.3.3}%
\contentsline {subsection}{\numberline {3.3.1}Measuring distance}{23}{subsection.3.3.1}%
\contentsline {subsubsection}{\numberline {3.3.1.1}Expected distance}{25}{subsubsection.3.3.1.1}%
\contentsline {subsubsection}{\numberline {3.3.1.2}Identifying a sample origin from RAP samples}{26}{subsubsection.3.3.1.2}%
\contentsline {subsection}{\numberline {3.3.2}Distance changes with different numbers of SNPs}{27}{subsection.3.3.2}%
\contentsline {section}{\numberline {3.4}Building a SNP-based genetic test}{27}{section.3.4}%
\contentsline {subsection}{\numberline {3.4.1}Pipeline}{27}{subsection.3.4.1}%
\contentsline {subsection}{\numberline {3.4.2}Implementation of a probabilistic test to identify samples}{28}{subsection.3.4.2}%
\contentsline {subsubsection}{\numberline {3.4.2.1}Classification}{28}{subsubsection.3.4.2.1}%
\contentsline {subsection}{\numberline {3.4.3}Some examples of genetic tests}{29}{subsection.3.4.3}%
\contentsline {subsubsection}{\numberline {3.4.3.1}Investigating cell line passages}{29}{subsubsection.3.4.3.1}%
\contentsline {subsubsection}{\numberline {3.4.3.2}Investigating individual relatedness}{29}{subsubsection.3.4.3.2}%
\contentsline {subsection}{\numberline {3.4.4}Genetic structure of the human population}{30}{subsection.3.4.4}%
\contentsline {subsubsection}{\numberline {3.4.4.1}Genes mirror geography in Europe}{31}{subsubsection.3.4.4.1}%
\contentsline {chapter}{\numberline {4}IGV (Integrative Genomics Viewer)}{33}{chapter.4}%
\contentsline {section}{\numberline {4.1}Main characteristics of IGV}{33}{section.4.1}%
\contentsline {subsection}{\numberline {4.1.1}Igvtools}{35}{subsection.4.1.1}%
\contentsline {subsection}{\numberline {4.1.2}Session Files}{35}{subsection.4.1.2}%
\contentsline {section}{\numberline {4.2}Some of the main utilizations}{36}{section.4.2}%
\contentsline {subsection}{\numberline {4.2.1}RNA-seq alignments}{36}{subsection.4.2.1}%
\contentsline {subsection}{\numberline {4.2.2}Study of variants}{36}{subsection.4.2.2}%
\contentsline {section}{\numberline {4.3}Interpreting Pair Orientations}{37}{section.4.3}%
\contentsline {subsection}{\numberline {4.3.1}Inversion}{37}{subsection.4.3.1}%
\contentsline {subsection}{\numberline {4.3.2}Tandem duplication}{38}{subsection.4.3.2}%
\contentsline {subsection}{\numberline {4.3.3}Inverted duplication}{38}{subsection.4.3.3}%
\contentsline {section}{\numberline {4.4}Summary}{39}{section.4.4}%
\contentsline {section}{\numberline {4.5}Exercise}{39}{section.4.5}%
\contentsline {subsection}{\numberline {4.5.1}Task B}{40}{subsection.4.5.1}%
\contentsline {chapter}{\numberline {5}Tumor Evolution Studies via NGS data}{42}{chapter.5}%
\contentsline {section}{\numberline {5.1}Tumor evolution}{42}{section.5.1}%
\contentsline {subsection}{\numberline {5.1.1}Tumor heterogeneity}{42}{subsection.5.1.1}%
\contentsline {subsubsection}{\numberline {5.1.1.1}Linear an branching evolution}{44}{subsubsection.5.1.1.1}%
\contentsline {subsection}{\numberline {5.1.2}Treatment resistance}{44}{subsection.5.1.2}%
\contentsline {section}{\numberline {5.2}From sketches to sequencing data evolution information}{45}{section.5.2}%
\contentsline {subsection}{\numberline {5.2.1}Tumor evolution and heterogeneity}{45}{subsection.5.2.1}%
\contentsline {subsubsection}{\numberline {5.2.1.1}Admixture}{46}{subsubsection.5.2.1.1}%
\contentsline {section}{\numberline {5.3}Useful measures from NGS pipeline}{46}{section.5.3}%
\contentsline {subsection}{\numberline {5.3.1}Informative SNPs in cancer studies}{46}{subsection.5.3.1}%
\contentsline {subsection}{\numberline {5.3.2}Coverage and AF properties}{47}{subsection.5.3.2}%
\contentsline {subsection}{\numberline {5.3.3}Computing Beta}{47}{subsection.5.3.3}%
\contentsline {section}{\numberline {5.4}Global vs Local Estimates of admixture}{49}{section.5.4}%
\contentsline {subsubsection}{\numberline {5.4.0.1}Estimate of DNA admixture (1-Purity)}{50}{subsubsection.5.4.0.1}%
\contentsline {section}{\numberline {5.5}A challenging case (PR-2741*)}{50}{section.5.5}%
\contentsline {chapter}{\numberline {6}Tumor evolution studies (continued)}{52}{chapter.6}%
\contentsline {section}{\numberline {6.1}Analysis of clonality}{52}{section.6.1}%
\contentsline {subsection}{\numberline {6.1.1}Recalls from previous chapter}{52}{subsection.6.1.1}%
\contentsline {subsection}{\numberline {6.1.2}Cluster analysis, an example}{52}{subsection.6.1.2}%
\contentsline {section}{\numberline {6.2}Evolution maps}{53}{section.6.2}%
\contentsline {subsection}{\numberline {6.2.1}A toy example}{54}{subsection.6.2.1}%
\contentsline {subsection}{\numberline {6.2.2}Working with real data}{55}{subsection.6.2.2}%
\contentsline {subsection}{\numberline {6.2.3}Pathway based evolution analysis}{56}{subsection.6.2.3}%
\contentsline {section}{\numberline {6.3}Ploidy and purity correction on $\log _2(\frac {T}{N})$ data}{57}{section.6.3}%
\contentsline {subsection}{\numberline {6.3.1}Melanoma example}{57}{subsection.6.3.1}%
\contentsline {subsubsection}{\numberline {6.3.1.1}Ploidy correction}{58}{subsubsection.6.3.1.1}%
\contentsline {subsubsection}{\numberline {6.3.1.2}Purity correction}{58}{subsubsection.6.3.1.2}%
\contentsline {subsection}{\numberline {6.3.2}Melanoma example with 25 samples}{58}{subsection.6.3.2}%
\contentsline {subsection}{\numberline {6.3.3}TCGA example}{59}{subsection.6.3.3}%
\contentsline {subsubsection}{\numberline {6.3.3.1}Ploidy in TCGA example}{60}{subsubsection.6.3.3.1}%
\contentsline {subsection}{\numberline {6.3.4}Allele-specific analysis}{62}{subsection.6.3.4}%
\contentsline {subsection}{\numberline {6.3.5}A Case study $CN_A$, $CN_B$ real data example}{64}{subsection.6.3.5}%
\contentsline {subsubsection}{\numberline {6.3.5.1}Application of longitudinal plasma profiling}{66}{subsubsection.6.3.5.1}%
\contentsline {chapter}{\numberline {7}Tumor evolution studies via NGS data: SNVs-based methods}{67}{chapter.7}%
\contentsline {section}{\numberline {7.1}Rationale of somatic point mutation based assays}{68}{section.7.1}%
\contentsline {section}{\numberline {7.2}TPES (Tumor Purity Estimation)}{68}{section.7.2}%
\contentsline {section}{\numberline {7.3}How many SNVs are needed to assess tumor purity?}{69}{section.7.3}%
\contentsline {section}{\numberline {7.4}Comparison between purity callers}{70}{section.7.4}%
\contentsline {section}{\numberline {7.5}Pros and Cons of SNVs-based tumor purity assessment}{70}{section.7.5}%
\contentsline {chapter}{\numberline {8}Liquid biopsies in oncology}{71}{chapter.8}%
\contentsline {section}{\numberline {8.1}General considerations}{71}{section.8.1}%
\contentsline {section}{\numberline {8.2}Issues in the interpretation of cfDNA data}{73}{section.8.2}%
\contentsline {subsection}{\numberline {8.2.1}Normalization on tumor content}{73}{subsection.8.2.1}%
\contentsline {subsection}{\numberline {8.2.2}Quantity of input material}{74}{subsection.8.2.2}%
\contentsline {section}{\numberline {8.3}SNV detection in liquid biopsies}{75}{section.8.3}%
\contentsline {section}{\numberline {8.4}Requirements depend on the application}{76}{section.8.4}%
\contentsline {section}{\numberline {8.5}Whole genome vs targeted sequencing}{76}{section.8.5}%
\contentsline {section}{\numberline {8.6}Case studies}{76}{section.8.6}%
\contentsline {subsection}{\numberline {8.6.1}Case I}{76}{subsection.8.6.1}%
\contentsline {subsection}{\numberline {8.6.2}Case II}{77}{subsection.8.6.2}%
\contentsline {section}{\numberline {8.7}Take-home message}{78}{section.8.7}%
\contentsline {subsection}{\numberline {8.7.1}Challenges in the tracking of tumor evolution}{78}{subsection.8.7.1}%
\contentsline {chapter}{\numberline {9}Extracellular vesicles}{79}{chapter.9}%
\contentsline {section}{\numberline {9.1}Definition}{79}{section.9.1}%
\contentsline {section}{\numberline {9.2}Characterization}{79}{section.9.2}%
\contentsline {subsection}{\numberline {9.2.1}Size}{80}{subsection.9.2.1}%
\contentsline {subsection}{\numberline {9.2.2}Origin}{80}{subsection.9.2.2}%
\contentsline {subsection}{\numberline {9.2.3}Content}{81}{subsection.9.2.3}%
\contentsline {section}{\numberline {9.3}The importance of EVs}{81}{section.9.3}%
\contentsline {subsection}{\numberline {9.3.1}Role in cancer}{81}{subsection.9.3.1}%
\contentsline {section}{\numberline {9.4}How can we use them to study cancer? (or any other disease)}{82}{section.9.4}%
\contentsline {subsection}{\numberline {9.4.1}Tracking tumor signal in serial samples}{83}{subsection.9.4.1}%
\contentsline {subsection}{\numberline {9.4.2}Different EVs isolation methods}{83}{subsection.9.4.2}%
\contentsline {chapter}{\numberline {10}Epigenetic profiling of cell-free DNA}{84}{chapter.10}%
\contentsline {section}{\numberline {10.1}Introduction}{84}{section.10.1}%
\contentsline {section}{\numberline {10.2}DNA methylation}{84}{section.10.2}%
\contentsline {section}{\numberline {10.3}How is DNA methylation measured?}{85}{section.10.3}%
\contentsline {section}{\numberline {10.4}Tissue-specific vs disease-specific DNA markers}{86}{section.10.4}%
\contentsline {section}{\numberline {10.5}DNA methylation based liquid biopsy}{86}{section.10.5}%
\contentsline {subsection}{\numberline {10.5.1}Workflow}{87}{subsection.10.5.1}%
\contentsline {subsection}{\numberline {10.5.2}CCGA study}{88}{subsection.10.5.2}%
\contentsline {subsection}{\numberline {10.5.3}Deconvolution approaches}{88}{subsection.10.5.3}%
\contentsline {section}{\numberline {10.6}Targeted panel approaches for tumor content estimation}{89}{section.10.6}%
\contentsline {part}{II\hspace {1em}Papers}{90}{part.2}%
\contentsline {chapter}{\numberline {11}Role of non-coding sequence variants in cancer}{91}{chapter.11}%
\contentsline {section}{\numberline {11.1}Abstract}{91}{section.11.1}%
\contentsline {subsection}{\numberline {11.1.1}Introduction}{91}{subsection.11.1.1}%
\contentsline {section}{\numberline {11.2}Genomic sequence variants}{91}{section.11.2}%
\contentsline {section}{\numberline {11.3}Non-coding element annotation}{92}{section.11.3}%
\contentsline {subsection}{\numberline {11.3.1}Cis regulatory regions}{92}{subsection.11.3.1}%
\contentsline {subsection}{\numberline {11.3.2}Distal regulatory elements}{92}{subsection.11.3.2}%
\contentsline {subsection}{\numberline {11.3.3}RNA-seq}{92}{subsection.11.3.3}%
\contentsline {subsection}{\numberline {11.3.4}Transcribed pseudogenes}{92}{subsection.11.3.4}%
\contentsline {subsection}{\numberline {11.3.5}Evolutionary conservation}{93}{subsection.11.3.5}%
\contentsline {section}{\numberline {11.4}Roles for somatic variants in cancer}{93}{section.11.4}%
\contentsline {subsection}{\numberline {11.4.1}Gain of TF-binding sites}{93}{subsection.11.4.1}%
\contentsline {subsection}{\numberline {11.4.2}Fusion events due to genomic rearrangements}{93}{subsection.11.4.2}%
\contentsline {subsection}{\numberline {11.4.3}ncRNAs and their binding sites}{93}{subsection.11.4.3}%
\contentsline {subsection}{\numberline {11.4.4}Role of pseudogenes in modulating the expression of a parental gene}{94}{subsection.11.4.4}%
\contentsline {section}{\numberline {11.5}Roles for germline variants in cancer}{94}{section.11.5}%
\contentsline {subsection}{\numberline {11.5.1}Promoter mutations}{94}{subsection.11.5.1}%
\contentsline {subsection}{\numberline {11.5.2}SNPs in enhancers}{94}{subsection.11.5.2}%
\contentsline {subsection}{\numberline {11.5.3}Variants in introns}{94}{subsection.11.5.3}%
\contentsline {subsection}{\numberline {11.5.4}SNPs in ncRNA and their binding sites}{94}{subsection.11.5.4}%
\contentsline {subsection}{\numberline {11.5.5}Others}{94}{subsection.11.5.5}%
\contentsline {section}{\numberline {11.6}Interplay between germline and somatic variants}{94}{section.11.6}%
\contentsline {section}{\numberline {11.7}Computational methods for identifying variants}{95}{section.11.7}%
\contentsline {section}{\numberline {11.8}Experimental approaches for functional validation}{95}{section.11.8}%
\contentsline {chapter}{\numberline {12}Advances in understanding cancer genomics through second-generation sequencing}{97}{chapter.12}%
\contentsline {section}{\numberline {12.1}Abstract}{97}{section.12.1}%
\contentsline {subsection}{\numberline {12.1.1}Introduction}{97}{subsection.12.1.1}%
\contentsline {section}{\numberline {12.2}Cancer-specific consideration}{97}{section.12.2}%
\contentsline {subsection}{\numberline {12.2.1}Characteristics of cancer samples for genomic analysis}{98}{subsection.12.2.1}%
\contentsline {subsection}{\numberline {12.2.2}Structural variability of cancer genomes}{98}{subsection.12.2.2}%
\contentsline {section}{\numberline {12.3}Experimental approaches}{98}{section.12.3}%
\contentsline {subsection}{\numberline {12.3.1}Whole genome sequencing}{98}{subsection.12.3.1}%
\contentsline {subsection}{\numberline {12.3.2}Exome sequencing}{98}{subsection.12.3.2}%
\contentsline {subsection}{\numberline {12.3.3}Transcriptome sequencing}{99}{subsection.12.3.3}%
\contentsline {section}{\numberline {12.4}Detecting classes of genome alterations}{99}{section.12.4}%
\contentsline {subsection}{\numberline {12.4.1}Somatic nucleotide substitutions and small insertion and deletion mutations}{99}{subsection.12.4.1}%
\contentsline {subsection}{\numberline {12.4.2}Copy number}{99}{subsection.12.4.2}%
\contentsline {subsection}{\numberline {12.4.3}Chromosomal rearrangements}{99}{subsection.12.4.3}%
\contentsline {subsection}{\numberline {12.4.4}Microbe-discovery methods}{100}{subsection.12.4.4}%
\contentsline {section}{\numberline {12.5}Computational issues}{100}{section.12.5}%
\contentsline {subsection}{\numberline {12.5.1}Alignment and assembly}{100}{subsection.12.5.1}%
\contentsline {subsection}{\numberline {12.5.2}mutations detection}{100}{subsection.12.5.2}%
\contentsline {subsection}{\numberline {12.5.3}Validation of mutation and rearrangement calls}{100}{subsection.12.5.3}%
\contentsline {chapter}{\numberline {13}Integrative genomics viewer}{102}{chapter.13}%
\contentsline {section}{\numberline {13.1}Introduction}{102}{section.13.1}%
\contentsline {chapter}{\numberline {14}Tumour heterogeneity and resistance to cancer therapies}{103}{chapter.14}%
\contentsline {section}{\numberline {14.1}Abstract}{103}{section.14.1}%
\contentsline {subsection}{\numberline {14.1.1}Introduction}{103}{subsection.14.1.1}%
\contentsline {section}{\numberline {14.2}Causes of intratumoral heterogeneity}{103}{section.14.2}%
\contentsline {subsection}{\numberline {14.2.1}Genomic instability}{103}{subsection.14.2.1}%
\contentsline {subsection}{\numberline {14.2.2}The clonal evolution and selection hypothesis}{104}{subsection.14.2.2}%
\contentsline {section}{\numberline {14.3}The spectrum of tumour heterogeneity}{104}{section.14.3}%
\contentsline {subsection}{\numberline {14.3.1}Spatial heterogeneity}{104}{subsection.14.3.1}%
\contentsline {subsubsection}{\numberline {14.3.1.1}Heterogeneity at a single disease site}{104}{subsubsection.14.3.1.1}%
\contentsline {subsubsection}{\numberline {14.3.1.2}Comparison of spatially distinct disease sites}{104}{subsubsection.14.3.1.2}%
\contentsline {subsection}{\numberline {14.3.2}Temporal heterogeneity}{105}{subsection.14.3.2}%
\contentsline {subsubsection}{\numberline {14.3.2.1}Genomic complexity might increase with exposure to targeted therapies}{105}{subsubsection.14.3.2.1}%
\contentsline {subsubsection}{\numberline {14.3.2.2}Longitudinal sampling provides insight into temporal heterogeneity}{105}{subsubsection.14.3.2.2}%
\contentsline {subsubsection}{\numberline {14.3.2.3}Residual drug-tolerant cells can foster temporal heterogeneity}{105}{subsubsection.14.3.2.3}%
\contentsline {section}{\numberline {14.4}Noninvasive monitoring of heterogeneity}{106}{section.14.4}%
\contentsline {subsection}{\numberline {14.4.1}Analysis of ctDNA}{106}{subsection.14.4.1}%
\contentsline {section}{\numberline {14.5}Overcoming heterogeneity}{106}{section.14.5}%
\contentsline {chapter}{\numberline {15}Unravelling the clonal hierarchy of somatic genomic aberrations}{108}{chapter.15}%
\contentsline {section}{\numberline {15.1}Introduction}{108}{section.15.1}%
\contentsline {subsection}{\numberline {15.1.1}Abstract}{108}{subsection.15.1.1}%
\contentsline {subsection}{\numberline {15.1.2}Background}{108}{subsection.15.1.2}%
\contentsline {section}{\numberline {15.2}Results}{109}{section.15.2}%
\contentsline {subsection}{\numberline {15.2.1}Clonality assessment of aberrations from sequencing reads}{109}{subsection.15.2.1}%
\contentsline {subsection}{\numberline {15.2.2}Inferring the order of mutations in a tumour sample}{110}{subsection.15.2.2}%
\contentsline {subsection}{\numberline {15.2.3}In silico and in situ experimental validation}{110}{subsection.15.2.3}%
\contentsline {subsection}{\numberline {15.2.4}Comparative analysis reveals different mechanisms of tumour deregulation}{110}{subsection.15.2.4}%
\contentsline {subsection}{\numberline {15.2.5}Clonal hierarchy of genomic aberrations}{111}{subsection.15.2.5}%
\contentsline {section}{\numberline {15.3}Materials and methods}{111}{section.15.3}%
\contentsline {subsection}{\numberline {15.3.1}CLONET pipeline}{111}{subsection.15.3.1}%
\contentsline {subsection}{\numberline {15.3.2}CLONET on exome and targeted sequencing data}{111}{subsection.15.3.2}%
\contentsline {subsection}{\numberline {15.3.3}Expected distribution of the allelic fraction of a genomic segment}{111}{subsection.15.3.3}%
\contentsline {subsection}{\numberline {15.3.4}Estimated proportion of neutral reads for a genomic segment}{112}{subsection.15.3.4}%
\contentsline {subsection}{\numberline {15.3.5}From neutral to non-aberrant reads}{112}{subsection.15.3.5}%
\contentsline {subsection}{\numberline {15.3.6}From aberrant reads to aberrant cells}{112}{subsection.15.3.6}%
\contentsline {subsection}{\numberline {15.3.7}Uncertainty assessment and its propagation to clonality estimates}{113}{subsection.15.3.7}%
\contentsline {subsection}{\numberline {15.3.8}Clonality of bi-allelic deletion}{113}{subsection.15.3.8}%
\contentsline {chapter}{\numberline {16}TPES: timor purity estimation from SNVs}{114}{chapter.16}%
\contentsline {section}{\numberline {16.1}Abstract}{114}{section.16.1}%
\contentsline {subsection}{\numberline {16.1.1}Introduction}{114}{subsection.16.1.1}%
\contentsline {section}{\numberline {16.2}Materials and methods}{114}{section.16.2}%
\contentsline {chapter}{\numberline {17}SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines}{116}{chapter.17}%
\contentsline {section}{\numberline {17.1}Abstract}{116}{section.17.1}%
\contentsline {subsection}{\numberline {17.1.1}Introduction}{116}{subsection.17.1.1}%
\contentsline {section}{\numberline {17.2}Material and methods}{116}{section.17.2}%
\contentsline {subsection}{\numberline {17.2.1}Genotype distance}{116}{subsection.17.2.1}%
\contentsline {subsection}{\numberline {17.2.2}SNP panel selection procedure}{117}{subsection.17.2.2}%
\contentsline {subsection}{\numberline {17.2.3}SPIA probabilistic test on cell line genotype distance}{117}{subsection.17.2.3}%
